• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Canopy Growth Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    10/14/25 6:06:24 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CGC alert in real time by email
    false 0001737927 Canopy Growth Corp 00-0000000 0001737927 2025-10-10 2025-10-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): October 10, 2025

     

     

     

    Canopy Growth Corporation

    (Exact name of registrant as specified in its charter)

     

     

     

    Canada   001-38496   N/A
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    1 Hershey Drive
    Smiths Falls, Ontario
    K7A 0A8
    (Address of principal executive offices) (Zip Code)

     

    (855) 558-9333

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading
    Symbol(s)
      Name of each exchange
    on which registered
    Common Shares, no par value   CGC   Nasdaq Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company    ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

     

     

     

     

     

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    On September 26, 2025, Canopy Growth Corporation (“Canopy Growth”) convened and adjourned to, and reconvened on, October 10, 2025, its 2025 Annual General and Special Meeting of Shareholders (the “Annual Meeting”). A total of 239,849,225 common shares of Canopy Growth (“Shares”) were entitled to vote as of August 1, 2025, the record date for the Annual Meeting. There were 79,971,625 Shares represented at the Annual Meeting, at which Canopy Growth’s shareholders were asked to vote on four proposals, each of which is described in more detail in Canopy Growth’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on August 7, 2025 (the “Proxy Statement”). Set forth below are the matters acted upon by Canopy Growth’s shareholders, and the final voting results of each such proposal.

     

    Proposal No. 1: Election of Director Nominees.

     

    Votes regarding the election of the five director nominees were as follows:

     

    Director Name  Votes For   Votes Against   Broker Non-Votes 
    David Lazzarato  35,477,544   3,160,608   41,333,472 
    Theresa Yanofsky  35,122,647   3,515,504   41,333,472 
    Luc Mongeau  35,745,175   2,892,976   41,333,472 
    Shan Atkins  35,631,069   3,007,082   41,333,472 
    Joe Bayern  35,899,799   2,738,353   41,333,472 

     

    Based on the votes set forth above, Canopy Growth’s shareholders elected each of the five nominees set forth above to serve as a director of Canopy Growth until the next annual general meeting of shareholders or until his or her successor is duly elected or appointed.

     

    Proposal No. 2: PKFOD Appointment.

     

    The proposal to appoint PKF O’Connor Davies, LLP, Certified Public Accountants (“PKFOD”), as Canopy Growth’s auditor and independent registered public accounting firm for the fiscal year ending March 31, 2026 and to authorize the board of directors of Canopy Growth (the “Board”) or any responsible committee thereof to fix their remuneration received the following votes:

     

    Votes For   Votes Withheld   Broker Non-Votes 
     75,518,055   4,453,570   — 

     

    Based on the votes set forth above, Canopy Growth’s shareholders approved the proposal to appoint PKFOD.

     

    Proposal No. 3: Share Consolidation Proposal

     

    The proposal to adopt a special resolution approving an amendment to Canopy Growth’s articles to, among other things, to provide that the authorized capital of Canopy Growth be altered by consolidating all of the issued and outstanding Shares and Canopy Growth exchangeable shares (the “Exchangeable Shares”) on the basis of a ratio to be determined by the Board, in its sole discretion, within a range of one post-consolidation share for every five to fifteen outstanding pre-consolidation shares, at anytime prior to September 26, 2026, with the exact ratio to be set at a whole number within this range by the Board in its sole discretion and applicable for both the Shares and Exchangeable Shares (the “Share Consolidation Resolution”), as further described in the Proxy Statement, received the following votes:

     

    Votes For   Votes Against   Abstain   Broker Non-Votes 
    62,742,664   16,557,315   671,647   — 

     

    Based on the votes set forth above, Canopy Growth’s shareholders approved the Share Consolidation Resolution.

     

     

     

    Proposal No. 4: Advisory, Non-Binding Vote on Compensation of Canopy Growth’s Named Executive Officers.

     

    The advisory (non-binding) vote on the compensation of Canopy Growth’s named executive officers (the “NEOs”), as set forth in the Proxy Statement, received the following votes:

     

    Votes For   Votes Against   Abstain   Broker Non-Votes 
    31,703,479   5,776,826   1,157,744   41,333,472 

     

    Based on the votes set forth above, Canopy Growth’s shareholders approved, on an advisory basis, the compensation of the NEOs.

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      CANOPY GROWTH CORPORATION
         
    By: /s/ Tom Stewart
        Tom Stewart
        Chief Financial Officer

     

    Date: October 14, 2025

     

     

    Get the next $CGC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGC

    DatePrice TargetRatingAnalyst
    4/4/2023Underperform → Mkt Perform
    Bernstein
    11/2/2022$1.50Underperform
    Bernstein
    10/26/2022Sell → Hold
    Canaccord Genuity
    6/8/2022Market Perform → Underperform
    BMO Capital Markets
    3/22/2022Equal Weight → Underweight
    Barclays
    3/1/2022$14.00 → $9.00Equal-Weight
    Barclays
    2/18/2022$9.60 → $11.00Neutral
    Cantor Fitzgerald
    12/22/2021Neutral → Underperform
    BofA Securities
    More analyst ratings

    $CGC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Canopy Growth Announces Results of Annual General and Special Meeting of Shareholders

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, is pleased to announce today the voting results from its Annual General and Special Meeting of Shareholders convened on September 26, 2025 and adjourned to, and reconvened on, October 10, 2025 (the "Meeting"). All of the matters put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated August 7, 2025 (the "Proxy Statement"), were approved by the requisite number of votes cast at the Meeting, as further detailed below. Each of t

    10/14/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Announces DOJA as Dedicated Canadian Medical Facility

    Kelowna site to produce craft cannabis under the DOJA brand exclusively for Spectrum Therapeutics patients, advancing Canopy Growth's commitment to Canada's medical market Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, today announced that its DOJA facility in Kelowna, British Columbia is now operating exclusively as a medical cultivation site supporting the Company's Spectrum Therapeutics portfolio in Canada. The Kelowna facility will cultivate small-batch, BC-grown craft cannabis under the DOJA brand, available only to registered Spectrum Therapeutics

    10/8/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    JP Brand Advisors and Canopy USA Form Strategic Partnership to Expand Hemp Beverage Distribution

    DALLAS, Oct. 7, 2025 /PRNewswire/ -- JP Brand Advisors ("JPBA"), the leading outsourced sales and strategy partner for beverage alcohol and emerging functional beverage brands, and Canopy USA, LLC ("Canopy USA"), a brand-driven organization strategically positioned across the U.S. cannabis market, today announced a strategic partnership to expand the distribution of Wana Wellness, LLC ("Wana")'s hemp-based beverages and gummies in the United States. The partnership underscores JPBA's expanding focus on hemp-based functional beverages, a category generating significant attentio

    10/7/25 8:01:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    SEC Filings

    View All

    Canopy Growth Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Canopy Growth Corp (0001737927) (Filer)

    10/14/25 6:06:24 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form DEFA14A filed by Canopy Growth Corporation

    DEFA14A - Canopy Growth Corp (0001737927) (Filer)

    9/26/25 2:49:17 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form DEFA14A filed by Canopy Growth Corporation

    DEFA14A - Canopy Growth Corp (0001737927) (Filer)

    9/24/25 4:15:25 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canopy Growth upgraded by Bernstein

    Bernstein upgraded Canopy Growth from Underperform to Mkt Perform

    4/4/23 9:09:41 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Bernstein initiated coverage on Canopy Growth with a new price target

    Bernstein initiated coverage of Canopy Growth with a rating of Underperform and set a new price target of $1.50

    11/2/22 6:11:10 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth upgraded by Canaccord Genuity

    Canaccord Genuity upgraded Canopy Growth from Sell to Hold

    10/26/22 7:36:52 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mongeau Luc bought $49,994 worth of shares (27,469 units at $1.82), increasing direct ownership by 3% to 812,368 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    9/23/25 4:15:11 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Bayern Joseph

    3 - Canopy Growth Corp (0001737927) (Issuer)

    10/14/25 4:15:35 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Lazzarato David Angelo sold $24,770 worth of shares (15,677 units at $1.58), decreasing direct ownership by 13% to 103,387 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    9/30/25 4:14:11 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Atkins M Shan sold $3,501 worth of shares (2,216 units at $1.58), decreasing direct ownership by 5% to 43,464 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    9/30/25 4:13:05 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Leadership Updates

    Live Leadership Updates

    View All

    Canopy Growth Announces Results of Annual General and Special Meeting of Shareholders

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, is pleased to announce today the voting results from its Annual General and Special Meeting of Shareholders convened on September 26, 2025 and adjourned to, and reconvened on, October 10, 2025 (the "Meeting"). All of the matters put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated August 7, 2025 (the "Proxy Statement"), were approved by the requisite number of votes cast at the Meeting, as further detailed below. Each of t

    10/14/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Appoints Tom Stewart as Chief Financial Officer

    Appointment finalizes CFO transition and reinforces Canopy Growth's focus on operational discipline, financial stability, and long-term value creation Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, today announced that Tom Stewart has been appointed Chief Financial Officer, effective immediately. Mr. Stewart's appointment supports the continued execution of Canopy Growth's fiscal year 2026 strategy, which is marked by structural efficiency, operational and commercial focus, and disciplined capital allocation and cost management. With significant progres

    9/17/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy USA Welcomes Cannabis Veteran Eric Ruhle as New Vice President of Brand Sales

    BOULDER, Colo., Aug. 27, 2025 /PRNewswire/ -- Canopy USA, LLC ("Canopy USA"), a brand-driven organization strategically positioned across the U.S. cannabis market, today announced the appointment of Eric Ruhle as Vice President of Brand Sales, overseeing sales strategy across the full Canopy USA portfolio. With more than 11 years of experience in the regulated cannabis industry, Ruhle brings deep expertise in building and leading high-performing sales organizations. Most recently, he served as Senior Regional Sales Manager at Kiva Sales & Services, where he navigated the highl

    8/27/25 8:01:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    4/19/24 5:00:49 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    11/3/23 4:30:53 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    7/20/23 4:35:52 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Financials

    Live finance-specific insights

    View All

    Canopy Growth Reports First Quarter Fiscal 2026 Financial Results; Cannabis Revenue Increased 24% Year-Over-Year

     Canada adult-use cannabis Q1 FY2026 net revenue increased 43% year-over-year, benefiting from increased distribution and strong consumer demand for new products, including Claybourne infused pre-roll joints Company has achieved $17MM of planned $20MM annualized savings target since March 1, 2025; SG&A expenses down 21% year-over-year in Q1 FY2026 compared to Q1 FY2025 Supply chain improvements in international markets expected to increase cannabis supply and consistency in margin accretive European markets in the second half of FY2026 Company expects to launch a new Storz & Bickel vaporizer during the second half of the calendar year Canopy Growth Corporation ("Canopy Growth" or th

    8/8/25 7:00:00 AM ET
    $CGC
    $DRI
    Medicinal Chemicals and Botanical Products
    Health Care
    Restaurants
    Consumer Discretionary

    Canopy Growth to Report First Quarter Fiscal 2026 Financial Results on August 8, 2025

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) will release its financial results for the first quarter fiscal year 2026 ended June 30, 2025 before financial markets open on August 8, 2025. Following the release of its first quarter fiscal year 2026 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Tom Stewart, Interim CFO on August 8, 2025 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=8135284A-F8CD-45B7-A384-634DE6714986 Replay Information A replay will be accessible by webcast until 11:59 PM ET on November 6, 2025 at:

    7/25/25 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    Canada cannabis revenue increased 4% in Q4 FY2025 year-over-year, led by 13% growth in Canada medical cannabis Reduced total debt by $293 million or 49% during FY2025 Refined strategy, focus and organizational structure expected to accelerate growth in global medical cannabis and improve commercial execution in Canada adult-use cannabis Additional cost reduction initiatives identified and initiated in Q4 FY2025 are expected to deliver at least $20 million in annualized savings over the next 12-18 months Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced its financial results for the fourth quarter ended March 31, 2025 ("Q4 FY2025") a

    5/30/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care